National Toxicology Program

National Toxicology Program

Testing Status of AZT + Rifabutin (AIDS Initiative) - M950055




  • 30516-87-1 - 3'-Azido-3'-deoxythymidine (AIDS)
  • 30516-87-1 - AZT transplacental carcinogenesis study
  • 72559-06-9 - Rifabutin

Known Uses

Combination therapy for treatment of AIDS

Organ Systems Toxicity

  • 30 days Repro/Dev Gen Tox (28-Day) (Gavage)  (RDGT95003)  Completed 
    • NIH Number: 00-3948
      Citation: NIEHS Technical Report on the Reproductive, Developmental, and General Toxicity Study of 3'-Azido-3'-deoxythymidine (AZT) and Rifabutin Combinations (CASRNs 30516-87-1 and 72559-06-9) Administered by Gavage to Swiss (CD-1®) Mice
    • Male and Female Mice: Swiss CD-1
    • Dose: 200 or 400 mg of AZT/kg/day and 80, 320, or 640 mg of rifabutin/kg/day.
NTP is located at the National Institute of Environmental Health Sciences, part of the National Institutes of Health.